New drug combo shows promise for Tough-to-Treat endometrial cancer
NCT ID NCT03526432
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing a combination of two drugs—atezolizumab (an immunotherapy) and bevacizumab (a drug that cuts off blood supply to tumors)—in 110 women with advanced, recurrent, or persistent endometrial cancer. The goal is to see how many patients experience tumor shrinkage or disappearance. Participants receive both drugs by IV every three weeks until the disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab and Bevacizumab (immunotherapy and anti-angiogenic drug combination)
What this could lead to
If successful, this combination could offer a new treatment option for women with advanced endometrial cancer that has not responded to standard chemotherapy.
What could go wrong
This is a phase II trial with a single group and no placebo, so results are preliminary. The combination may not improve outcomes and could cause side effects like high blood pressure or immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73117, United States
-
UAB Women and Infants Center
Birmingham, Alabama, 35233, United States
-
Washington University School of Medicine
St Louis, Missouri, 63108, United States